 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...224225226227228229230231232233234235236» |
- oxaliplatin / Generic mfg., erlotinib / Generic mfg.
Trial termination, Surgery, Metastases: Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 2, 2012
P2, N=7, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Terminated; For slow accrual
- oxaliplatin / Generic mfg., erlotinib / Generic mfg.
Enrollment change, Surgery, Metastases: Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 2, 2012
P2, N=7, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Terminated; For slow accrual N=25 --> 7
- buparlisib (AN2025) / Adlai Nortye
New P1 trial, Metastases: BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (clinicaltrials.gov) - Apr 2, 2012
P1, N=60, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 2, 2012
P2, N=120, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=25 --> 7 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly
Enrollment change, Surgery: PETACC-8: Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery (clinicaltrials.gov) - Apr 1, 2012
P3, N=2564, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Not yet recruiting --> Recruiting N=2000 --> 2564
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients. Studio randomizatto di fase II con FOLFIRI piu' CETUXIMAB o FOLFIRI da solo in pazienti anziani affetti da tumore colo-rettale avanzato. (EUDRACT) - Apr 1, 2012
P2, N=74, Ongoing, Sponsor: AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
- | Erbitux (cetuximab) / Eli Lilly
Trial completion, Surgery: PETACC-8: Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery (clinicaltrials.gov) - Apr 1, 2012
P3, N=2564, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
N=2000 --> 2564 Recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy, Metastases: Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment (clinicaltrials.gov) - Mar 26, 2012
P2, N=58, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed N=86 --> 58
- | Erbitux (cetuximab) / Eli Lilly
New P4 trial, Combination therapy, Metastases: Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 26, 2012
P4, N=150, Recruiting, Sponsor: Xu jianmin
- PF-04136309 / Pfizer
Enrollment open, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 26, 2012
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine
N=86 --> 58 Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy, Metastases: Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment (clinicaltrials.gov) - Mar 26, 2012
P2, N=58, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || New P3 trial, Metastases: FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Mar 25, 2012
P3, N=200, Not yet recruiting, Sponsor: Sun Yat-sen University
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial: Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Mar 20, 2012
P2, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
- melphalan / Generic mfg.
Trial completion, Metastases: Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver (clinicaltrials.gov) - Mar 20, 2012
P2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas (clinicaltrials.gov) - Mar 20, 2012
P1, N=108, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Davanat (galactomannan) / Galectin Therap
Trial termination, Combination therapy, Metastases: A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer (clinicaltrials.gov) - Mar 12, 2012
P2, N=10, Terminated, Sponsor: Galectin Therapeutics Inc.
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Financing and re-organization
- Davanat (galactomannan) / Galectin Therap
Enrollment change, Combination therapy, Metastases: A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer (clinicaltrials.gov) - Mar 12, 2012
P2, N=10, Terminated, Sponsor: Galectin Therapeutics Inc.
Active, not recruiting --> Terminated; Financing and re-organization N=50 --> 10
- | Stivarga (regorafenib) / Bayer
New P2 trial, Combination therapy, Metastases: A study to assess if regorafenib when given in combination with standard chemotherapy (FOLFIRI) will result in increased survival, without the cancer getting worse, as compared to a non-active treatment (placebo) given in combination with standard chemotherapy (FOLFIRI). The study will be conducted in a sub-group of metastatic colorectal cancer patients who have failed on their 1st oxaliplatin containing chemotherapy regimen. (EUDRACT) - Mar 7, 2012
P2, N=240, Ongoing, Sponsor: The Irish Clinical Oncology Research Group
- Enrollment open, Metastases: S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 7, 2012
P2, N=225, Recruiting, Sponsor: Southwest Oncology Group
N=50 --> 10 Not yet recruiting --> Recruiting
- ||||| thioguanine / Generic mfg., clofarabine / Generic mfg.
Trial initiation date: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 6, 2012
P3, N=4895, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Initiation date: Aug 2011 --> Feb 2012
- |||||| thioguanine / Generic mfg., clofarabine / Generic mfg.
Enrollment open: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 6, 2012
P3, N=4895, Recruiting, Sponsor: Children's Oncology Group
Initiation date: Aug 2011 --> Feb 2012 Not yet recruiting --> Recruiting
- melphalan / Generic mfg.
Trial completion, Metastases: Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Mar 6, 2012
P3, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 5, 2012
P2, N=128, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Metastases: High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer (clinicaltrials.gov) - Mar 1, 2012
P2, N=135, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || brivanib alaninate (BMS-582664) / ZAI Lab
Enrollment closed, Combination therapy, Metastases: Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) (clinicaltrials.gov) - Feb 29, 2012
P1, N=72, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Metastases: AFFIRM: Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 29, 2012
P2, N=268, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Erivedge (vismodegib) / Roche
Enrollment change: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study (clinicaltrials.gov) - Feb 28, 2012
P2, N=19, Completed, Sponsor: Genentech
Active, not recruiting --> Completed N=250 --> 19
- Avastin (bevacizumab) / Roche
New P2 trial: PERIMAX: Perioperative Treatment of Resectable Liver Metastases (clinicaltrials.gov) - Feb 26, 2012
P2, N=0, Withdrawn, Sponsor: University of Regensburg
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., floxuridine / Generic mfg.
Trial completion, Metastases: Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer (clinicaltrials.gov) - Feb 26, 2012
P2, N=28, Completed, Sponsor: New York University School of Medicine
N=250 --> 19 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Metastases: Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 22, 2012
P2, N=169, Active, not recruiting, Sponsor: Cheryl Pugh
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- sunitinib / Generic mfg.
Enrollment closed, Metastases: Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer (clinicaltrials.gov) - Feb 21, 2012
P1, N=30, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- pyrimethamine / Generic mfg.
Trial completion: Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) (clinicaltrials.gov) - Feb 21, 2012
P1/2, N=20, Completed, Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting Recruiting --> Completed
- robatumumab (SCH 717454) / Merck (MSD)
Trial termination: Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) (clinicaltrials.gov) - Feb 20, 2012
P1b/2, N=15, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Completed --> Terminated; This study was terminated for business reasons.
- sunitinib / Generic mfg.
Enrollment closed, Metastases: SUN-CASE: Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI (clinicaltrials.gov) - Feb 16, 2012
P2, N=90, Active, not recruiting, Sponsor: PD Dr Markus M
Completed --> Terminated; This study was terminated for business reasons. Recruiting --> Active, not recruiting
- |||| Kinenza (enzastaurin) / Denovo, Aytu BioPharma, Avastin (bevacizumab) / Roche
Trial completion, Metastases: Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer (clinicaltrials.gov) - Feb 16, 2012
P2, N=150, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || dactinomycin / Generic mfg.
New P3 trial: Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia (clinicaltrials.gov) - Feb 15, 2012
P3, N=384, Recruiting, Sponsor: Gynecologic Oncology Group
- | Enrollment open: PRODIGE-24: Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 14, 2012
P3, N=490, Recruiting, Sponsor: UNICANCER
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Feb 9, 2012
P2, N=32, Recruiting, Sponsor: Second Military Medical University
- | pentamidine oral (VLX103) / Odan Labs
Enrollment change, Metastases: Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (clinicaltrials.gov) - Feb 6, 2012
P2, N=48, Active, not recruiting, Sponsor: Oncozyme Pharma Inc.
Not yet recruiting --> Recruiting N=31 --> 48
- | oxaliplatin / Generic mfg.
New P2 trial, Metastases: Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer (clinicaltrials.gov) - Feb 6, 2012
P2, N=51, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Metastases: Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma (clinicaltrials.gov) - Feb 4, 2012
P2, N=24, Completed, Sponsor: University of Michigan Cancer Center
N=31 --> 48 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial termination, Metastases: Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer (clinicaltrials.gov) - Feb 1, 2012
P=N/A, N=2, Terminated, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Completed --> Terminated; Lack of accrual
- || New P3 trial: PRODIGE-24: Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 1, 2012
P3, N=490, Recruiting, Sponsor: UNICANCER
- Erbitux (cetuximab) / Eli Lilly
New P2 trial, Combination therapy, Metastases: A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (clinicaltrials.gov) - Jan 30, 2012
P2, N=8, Terminated, Sponsor: Austrian Breast & Colorectal Cancer Study Group
- | New P2 trial, Metastases: Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jan 30, 2012
P2, N=67, Recruiting, Sponsor: Yale University
- | irinotecan / Generic mfg.
New P2 trial, Metastases: Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jan 30, 2012
P2, N=500, Active, not recruiting, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- Trial completion, Metastases: Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC (clinicaltrials.gov) - Jan 30, 2012
P2, N=50, Completed, Sponsor: Samsung Medical Center
Completed --> Terminated; Lack of accrual Recruiting --> Completed
- ||||| Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: Colorectal Cancer (CRC) Cetuximab Elderly Frail (clinicaltrials.gov) - Jan 29, 2012
P2, N=150, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- | sunitinib / Generic mfg.
Trial termination, Metastases: Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 26, 2012
P2b, N=191, Terminated, Sponsor: Pfizer
Recruiting --> Completed Completed --> Terminated; See termination reason in detailed description.
- Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Trial initiation date, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 25, 2012
P1, N=33, Active, not recruiting, Sponsor: Genentech
Completed --> Terminated; See termination reason in detailed description. Initiation date: Apr 2011 --> Jul 2011